Onkologiezentrum Donauwörth

The research at Onkologiezentrum Donauwörth focuses on advanced ER‑positive, HER2‑negative breast cancer, evaluating newer endocrine strategies to improve progression‑free survival. Trials compare a selective estrogen receptor degrader with standard endocrine options and explore the added benefit of a CDK4/6 inhibitor, especially in patients harboring ESR1 mutations.

• Optimization of endocrine therapy sequencing
• Impact of ESR1 mutations on treatment response
• Combination of selective estrogen receptor degraders and CDK4/6 inhibitors
• Progression‑free survival as primary efficacy endpoint

The site’s multidisciplinary team supports patient enrollment and monitors outcomes to advance personalized breast‑cancer care.

At Onkologiezentrum Donauwörth, investigators are studying high‑risk chronic lymphocytic leukemia defined by genetic abnormalities such as 17p deletion, TP53 mutation, complex karyotype, or unmutated IGHV. The goal is to assess whether a triple regimen of a BTK inhibitor, an anti‑CD20 antibody, and a BCL‑2 antagonist can extend progression‑free survival compared with a double‑therapy backbone.

• High‑risk genetic profiling for patient stratification
• Targeted BTK inhibition combined with anti‑CD20 therapy
• Integration of BCL‑2 inhibition to deepen responses
• Evaluation of progression‑free survival benefits

The center provides comprehensive care for CLL patients, facilitating access to innovative combination treatments.